A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells.

Riki Toita,Masaharu Murata,Kana Abe,Sayoko Narahara,Jing Shu Piao,Jeong-Hun Kang,Makoto Hashizume

CHEMICAL COMMUNICATIONS（2013）

引用 43|浏览17

暂无评分

摘要

Herein, we report the preparation of genetically engineered protein cages (HspG41C-SP94), taken up selectively by human hepatocellular carcinoma (HCC) cells. An engineered protein cage-doxorubicin (DOX) conjugate was as cytotoxic as free DOX against HCC cells but much less cytotoxic against normal hepatocytes.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要